Reports Q3 revenue $673,000, consensus $2.37M. “The third quarter marked the first patients receiving Omisirge following FDA approval and the point at which Gamida Cell truly transitioned to a commercial-stage company with our first revenue reported,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. “Our lean launch prioritized two key performance indicators – transplant center onboarding and market access – both of which have surpassed our expectations, ahead of schedule. We anticipate continuing to onboard additional transplant centers, leading to a ramp-up of patients and Omisirge deliveries in the coming months.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMDA:
- Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
- Gamida Cell (GMDA) Q3 Earnings Cheat Sheet
- Gamida Cell presents new data on allogeneic stem cell therapy Omidubicel, GDA-20
- Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Gamida Cell reports preliminary data from phase 1 study of GDA-201
